


VALUATION MULTIPLES

Forward EV / EBITDA Multiples (monthly to 30/06/2019) Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of June, the sector traded on a forward EV / EBITDA multiple of 11.8x, compared to the ASX200 on 9.7x.



Average Values and Trading Multiples (values as at 18/07/2019) Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2019	EV/EBIT FY2019	Price / Earnings FY2019
Aged Care	3,613	12.2x	17.3x	17.0x
Animal Health	258	9.2x	11.6x	14.6x
Biotech	106,270	25.5x	28.8x	36.8x
Hospitals & Clinics	45,164	11.5x	15.4x	19.9x
Medical Devices	14,557	31.6x	34.9x	47.5x
Healthcare	171,014	13.0x	16.7x	20.6x

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2019. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result.

MERGER & ACQUISITION NEWS...



Value: \$23m

Australian pharma manufacturer and distributor **Probiotec** has entered into an agreement to acquire **Australian Blister Sealing** for AUD 23m. The acquisition will be settled in cash, for a base amount of AUD 23m, subject to normal adjustments.



UNDER THE MICROSCOPE...

- **CSL**, the Australian protein-based biotechnology group, is most likely to make acquisitions of emerging therapies, such as gene therapy or FcRn therapy.
- A subsidiary of India-based **Strides Pharma Science** has signed definitive agreements to exit from its investment in Australia-based **Arrow Pharma**.
- **Bionic Vision Technologies (BVT)**, an Australia-based retinal implant innovator, plans to list on the ASX within the next 12 months, seeking cornerstone investor.
- Hong Kong-based **Health and Happiness** is anticipated to buy a 15% to 20% stake in **Bod Australia**, an Australia-based natural medicine and beauty products developer and distributor.
- **Ford Health**, an Australian privately held provider of corporate health and wellness programs, is seeking a strategic partner from the healthcare technology sector as part of the company's plans to improve its patient data platform.
- **Medibank Private**, an Australia-based health insurance business, could receive takeover interest before shareholder restrictions lapse on 1 December.
- **UnitingCare Australia**, an Australia-based aged-care services provider, is said to be among bidders interested in **KinCare**, an Australian aged-care business. **KinCare** has been presented as a business with revenue of over AUD 100m.

CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Managing Director	(07) 3218 9122	sdoyle@interfinancial.com.au
Paul Keehan	Chairman	(07) 3218 9100	pkeehan@interfinancial.com.au
Mark Steinhardt	Head of M&A	(07) 3218 9105	msteinhardt@interfinancial.com.au
Brad Shaw	Chief Operating Officer	(07) 3218 9100	bshaw@interfinancial.com.au
David Hassum	Director	(07) 3218 9108	dhassum@interfinancial.com.au
Andrew Wheeler	Director	(07) 3218 9107	awheeler@interfinancial.com.au
Anna Green	Director	(07) 3218 9100	agreen@interfinancial.com.au
Ted Marchant	Director	(07) 3218 9100	tmarchant@interfinancial.com.au
Sally McMillan	Associate Director	(07) 3218 9100	smcmillan@interfinancial.com.au
Tom Benham	Associate Director	(07) 3218 9113	tbenham@interfinancial.com.au
Michael Kakanis	Associate	(07) 3218 9106	mkakanis@interfinancial.com.au

DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

Important Disclaimer – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

Disclosure. InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.

InterFinancial
Corporate Finance Limited
ABN: 49 136 962 966
AFSL: 341675
Level 2, 201 Charlotte Street
GPO Box 975
Brisbane Queensland 4001
(07) 3218 9100
admin@interfinancial.com.au
www.interfinancial.com.au

